RSS Feeds
Thrombocytosis Associated with Low-Molecular-Weight Heparin
The Editors welcome submissions for possible publication in the Letters section. Authors of letters should:
•Include no more than 300 words of text, three authors, and five references
•Type with double-spacing
•Send three copies of the letter, an authors' form signed by all authors, and a cover letter describing any conflicts of interest related to the contents of the letter.
Letters commenting on an Annals article will be considered if they are received within 6 weeks of the time the article was published. Only some of the letters received can be published. Published letters are edited and may be shortened; tables and figures are included only selectively. Authors will be notified that the letter has been received. If the letter is selected for publication, the author will be notified about 3 weeks before the publication date. Unpublished letters cannot be returned.
Annals welcomes electronically submitted letters.
TO THE EDITOR:
Rizzieri and coworkers [1] report a case of thrombocytosis that they attribute to treatment with enoxaparin. The patient had metastatic carcinoma and was asplenic; enoxaparin was given for pulmonary embolism. The platelet count was normal (285 cells/mm3) before enoxaparin treatment, increased to 1114 cells/mm3 within 4 weeks of treatment, and became normal after chemotherapy for carcinoma and discontinuation of enoxaparin therapy. I propose an alternate explanation for these findings. I suspect that the patient had the Trousseau syndrome with disseminated intravascular coagulation and rapid platelet consumption. A platelet count of more than 1 million cells/mm3 could result from the combination of metastatic carcinoma and asplenia [2]; the increase in platelet count after enoxaparin treatment may therefore have represented a return to “baseline” as a result of suppression of disseminated intravascular coagulation by enoxaparin rather than an increase in platelet production induced by that drug.
The Editors welcome submissions for possible publication in the Letters section. Authors of letters should:
•Include no more than 300 words of text, three authors, and five references
•Type with double-spacing
•Send three copies of the letter, an authors' form signed by all authors, and a cover letter describing any conflicts of interest related to the contents of the letter.
Letters commenting on an Annals article will be considered if they are received within 6 weeks of the time the article was published. Only some of the letters received can be published. Published letters are edited and may be shortened; tables and figures are included only selectively. Authors will be notified that the letter has been received. If the letter is selected for publication, the author will be notified about 3 weeks before the publication date. Unpublished letters cannot be returned.
Annals welcomes electronically submitted letters.
- Copyright ©2004 by the American College of Physicians
